Cue Biopharma, Inc. (CUE) Investor Relations Documents

Cue Biopharma, Inc. (CUE) investor relations documents from the company's IR site: 1 presentation, 24 press releases; latest deck 2026-04-07. Read in-app with summaries. First-party data.

Download Presentation ›: Cue Biopharma is advancing CUE-401, a bifunctional cytokine therapeutic for autoimmune disease, with an IND filing scheduled for the second quarter of 2026.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-14Press releasePDF Version
2026-08-14Press releaseCue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
2026-08-03Press releasePDF Version
2026-08-03Press releaseCue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug S
2026-07-13Press releasePDF Version
2026-07-13Press releaseCue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development
2026-07-10Press releasePDF Version
2026-07-09Press releaseCue Biopharma Announces $50.0 Million Private Placement
2026-07-09Press releaseCue Biopharma Announces $50.0 Million Private Placement
2026-06-26Press releaseCue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic Developments
2026-06-02Press releasePDF Version
2026-06-02Press releaseCue Biopharma Announces Board Transition and Addition of New Directors with Continued Company Evolution
2026-05-14Press releasePDF Version
2026-05-14Press releaseCue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic Developments
2026-05-07Press releasePDF Version
2026-05-07Press releaseCue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-04-30Press releasePDF Version
2026-04-30Press releasePDF Version
2026-04-30Press releasePDF Version
2026-04-30Press releaseCue Biopharma Names Shao-Lee Lin M.D., Ph.D., CEO, President and Board Director to Lead Continued Growth and Transformat
2026-04-30Press releaseCue Biopharma Expands Pipeline with Exclusive License from Ascendant Health Sciences Ltd. for Clinical-Stage Dual-Mechan
2026-04-30Press releaseCue Biopharma Announces $30 Million Private Placement
2026-04-30Press releaseCue Biopharma Expands Pipeline with Exclusive License from Ascendant Health Sciences Ltd. for Clinical-Stage Dual-Mechan
2026-04-07PresentationDownload Presentation ›
2025-12-19Press releaseCue Biopharma Announces Pricing of $10 Million Public Offering

CUE overview · CUE earnings · CUE financials · CUE KPIs · CUE ownership · CUE peers · CUE filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.